Chugai’s ALK Inhibitor Trial Stopped Early Due to Benefit

Japan’s Chugai stopped a Phase 3 trial of its ALK inhibitor Alecensa due to a significant improvement in progression-free survival in non-small cell lung cancer.

The head-to-head trial compared Alecensa to Pfizer’s ALK inhibitor Zalkori in 207 patients with  ALK fusion gene positive advanced or recurrent NSCLC who either had not undergone chemotherapy or had undergone one chemotherapy regimen. The data monitoring committee recommended the trial stop early following a planned interim peek at the data.